Merck (MRK) 주식 개요
는 전 세계 헬스케어 회사로 운영되고 있습니다. 자세히 보기
MRK Community Fair Values
Create NarrativeSee what 653 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
US$112.55
FV
0.4% 고평가 내재 할인율5.25%
Revenue growth p.a.
247
users have viewed this narrative2users have liked this narrative
0users have commented on this narrative
13users have followed this narrative
Merck & Co., Inc. 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | US$113.00 |
| 52주 최고가 | US$125.14 |
| 52주 최저가 | US$75.40 |
| 베타 | 0.20 |
| 1개월 변동 | -3.50% |
| 3개월 변동 | -7.27% |
| 1년 변동 | 46.79% |
| 3년 변동 | -0.53% |
| 5년 변동 | 46.32% |
| IPO 이후 변동 | 9,944.44% |
최근 뉴스 및 업데이트
내러티브 업데이트 • May 19
Merck Completes Acquisition of Terns Pharmaceuticals
Strengthening Hematology Pipeline with Breakthrough CML Therapy Candidate TERN-701 Analyst: Qudus Adsebara (Founder, Wane Investment House) Transaction Overview Merck & Co Inc (NYSE: MRK), known as MSD outside the United States and Canada, has successfully completed the acquisition of Terns Pharmaceuticals Inc following the conclusion of its cash tender offer and merger process. The acquisition reinforces Merck’s strategy of expanding its oncology and hematology pipeline through science-driven and value-enhancing business development initiatives.
내러티브 업데이트 • May 17
MRK: Oncology Pipeline And Terns Deal Will Shape Forward Risk Balance
Merck's analyst fair value estimate is now $129.74. Analysts link this adjustment and modestly higher assumed revenue growth and P/E multiples to recent price target increases from firms such as Wells Fargo, UBS, JPMorgan, Citi, Morgan Stanley, RBC, and Barclays following pipeline updates and the Terns acquisition.Seeking Alpha • May 16
A Futuristic Synthesis Indeed
Summary A recent paper by Merck details the industrial synthesis of enlicitide, which is a beast of a macrocyclic peptide. Just looking at the structure tells you that this must be a ferociously active molecule with huge commercial potential, because there is just no way that anyone is going to make this on scale - or find a way to make this on scale! - otherwise. Several companies have tried over the years to come up with a small-molecule approach that could lead to an orally dosed therapy as opposed to an injectable, and Merck has apparently made it over the finish line with this one. Read the full article on Seeking AlphaRecent updates
내러티브 업데이트 • May 19
Merck Completes Acquisition of Terns Pharmaceuticals
Strengthening Hematology Pipeline with Breakthrough CML Therapy Candidate TERN-701 Analyst: Qudus Adsebara (Founder, Wane Investment House) Transaction Overview Merck & Co Inc (NYSE: MRK), known as MSD outside the United States and Canada, has successfully completed the acquisition of Terns Pharmaceuticals Inc following the conclusion of its cash tender offer and merger process. The acquisition reinforces Merck’s strategy of expanding its oncology and hematology pipeline through science-driven and value-enhancing business development initiatives.내러티브 업데이트 • May 17
MRK: Oncology Pipeline And Terns Deal Will Shape Forward Risk Balance
Merck's analyst fair value estimate is now $129.74. Analysts link this adjustment and modestly higher assumed revenue growth and P/E multiples to recent price target increases from firms such as Wells Fargo, UBS, JPMorgan, Citi, Morgan Stanley, RBC, and Barclays following pipeline updates and the Terns acquisition.Seeking Alpha • May 16
A Futuristic Synthesis Indeed
Summary A recent paper by Merck details the industrial synthesis of enlicitide, which is a beast of a macrocyclic peptide. Just looking at the structure tells you that this must be a ferociously active molecule with huge commercial potential, because there is just no way that anyone is going to make this on scale - or find a way to make this on scale! - otherwise. Several companies have tried over the years to come up with a small-molecule approach that could lead to an orally dosed therapy as opposed to an injectable, and Merck has apparently made it over the finish line with this one. Read the full article on Seeking Alpha분석 기사 • May 11
Merck's (NYSE:MRK) Soft Earnings Don't Show The Whole Picture
Shareholders appeared unconcerned with Merck & Co., Inc.'s ( NYSE:MRK ) lackluster earnings report last week. Our...
내러티브 업데이트 • May 02
MRK: Oncology Reorg And Deals For Targeted Therapies Will Support Higher P E Multiple
Analysts nudged the Merck price target higher by a few dollars per share, reflecting updated expectations for slightly lower revenue growth, a modestly higher profit margin, and a somewhat lower future P/E multiple, supported by recent research commentary on the pipeline and business development moves. Analyst Commentary Recent research has tilted positive around Merck, with several large firms adjusting their models and price targets to reflect updated views on the pipeline, partnered programs, and business development activity.내러티브 업데이트 • Apr 19
Merck & Co., Inc. – Tender Offer for Terns Pharmaceuticals, Inc. (Full Acquisition Transaction)
Author: Qudus Adebara (Founder of Wane Investment House) Transaction Overview Merck & Co., Inc. (known as MSD outside the U.S. and Canada) has formally commenced a cash tender offer to acquire all outstanding shares of Terns Pharmaceuticals, Inc., following the signing of a definitive agreement on March 25, 2026.내러티브 업데이트 • Apr 18
MRK: Oncology Reorg And Pipeline Deals Will Support Higher Future P E Multiple
Analysts have lifted their Merck price targets by up to the mid double digits in recent weeks, citing higher modeled revenue growth, slightly stronger profit margins, and updated views on future P/E multiples as Merck advances its pipeline and business development moves. Analyst Commentary Recent Street research on Merck has been broadly constructive, with a cluster of price target revisions and fresh initiations pointing to confidence in the company’s execution, pipeline progress, and M&A activity.
내러티브 업데이트 • Apr 04
MRK: M&A Execution Risks Around Terns And Revolution Will Restrain Future Upside
Analysts have nudged Merck's fair value estimate higher to approximately $101.30, reflecting updated assumptions for slightly stronger revenue growth, a modestly higher profit margin, and a marginally lower future P/E. This view is supported by a wave of recent price target increases into the $130 to $150 range and fresh Outperform or Overweight initiations on the stock.내러티브 업데이트 • Mar 21
MRK: Pipeline Readouts And Oncology Reorg Will Support Higher Future P E Multiple
The analyst price target for Merck has been reset from $136 to $150. This reflects analysts' updated assumptions for modestly higher revenue growth, a stronger profit margin profile, and a slightly lower future P/E multiple, supported by recent research that highlights potential upside from Sac TMT, upcoming launches, and key Phase 3 readouts.내러티브 업데이트 • Mar 06
MRK: Keytruda Cliff And M&A Uncertainty Will Likely Curb Long Term Upside
Analysts have lifted their Merck fair value estimate from $83.00 to about $101.04, pointing to broad price target hikes across the Street and citing confidence in upcoming product launches, Phase 3 readouts, and management's approach to the Keytruda loss of exclusivity. Analyst Commentary Recent research coverage on Merck has tilted positive, with several firms lifting price targets and starting the stock with favorable ratings.내러티브 업데이트 • Feb 20
MRK: Pipeline Readouts And Gardasil Policy Shifts Will Shape Forward Risk Balance
Analysts have lifted their Merck fair value estimate from $115.11 to $124.88, citing a higher expected future P/E, modestly higher projected revenue growth, and a series of recent price target hikes that highlight confidence in upcoming launches and data readouts. Analyst Commentary Recent Street research around Merck points to a generally constructive tone, with many firms adjusting ratings and price targets in a way that supports a higher fair value, while still flagging a few execution and policy watchpoints for investors to track.내러티브 업데이트 • Feb 06
MRK: Rising Confidence In Pipeline Execution To Support Richer Future P E Multiple
Analysts have nudged our Merck fair value estimate higher to $136, reflecting a higher average price target across firms such as Scotiabank, Goldman Sachs, BMO, BofA, Citi, Wells Fargo, Bernstein, Cantor Fitzgerald, TD Cowen, and others, who cite stronger top line expectations, updated margin assumptions, and a richer future P/E multiple. Analyst Commentary Across recent research, bullish analysts are largely aligned in their view that Merck is executing well enough to support higher valuation assumptions.
새로운 내러티브 • Jan 30
The Oncology Anchor: Why Merck’s 46% Discount Defies the Keytruda Cliff
Merck’s 2026 narrative is a high-stakes drama centered on Keytruda , the world’s top-selling cancer drug. For years, the market has treated Merck like a "one-trick pony" due to the looming 2028 "patent cliff," where Keytruda will lose its legal protection and face generic competition.내러티브 업데이트 • Jan 23
MRK: M&A Pipeline And Gardasil Policy Shifts Will Shape Future Risk Balance
Analysts lifted their Merck fair value estimate by about $8.50 to $115.11 per share as they factor in a higher future P/E multiple, recent price target increases from several firms, and growing confidence in the company being added to BofA's "US 1 List." Analyst Commentary Recent research on Merck gives you a mix of confidence in the company’s execution and some clear areas to watch. Here is how the current commentary breaks down.내러티브 업데이트 • Jan 09
MRK: Cidara Flu Deal Will Likely Highlight Overstated Long Term Hopes
Narrative Update The analyst price target for Merck has moved higher to a range of about $105 to $135. Analysts point to sector re-ratings, recent upgrades to Outperform, and confidence in the company’s product pipeline and deal activity as key drivers of their updated views.내러티브 업데이트 • Dec 24
MRK: Cidara Flu Deal Will Likely Expose Overstated Long Term Expectations
Analysts have nudged their fair value estimate for Merck higher, lifting the price target by $1 to $83 as they factor in stronger revenue growth, improved profit margins, and a lower future P/E multiple supported by recent positive research initiations and deal activity. Analyst Commentary Street research around Merck has turned more constructive in recent weeks, with several firms highlighting an improving growth outlook and a more attractive risk reward profile.내러티브 업데이트 • Dec 14
Merck predicts unstoppable growth with KEYTRUDA and WINREVAIR hitting record hihs
based on Q3 result내러티브 업데이트 • Dec 10
MRK: Cidara Acquisition And Patent Overhang Will Shape Future Risk Reward Balance
Analysts have modestly raised their fair value estimate for Merck to approximately $106.62 from about $104.27 per share, citing the higher Street price target of $105, growing confidence in its infectious disease and oncology pipeline, and the view that shares remain attractively valued relative to the company's long term growth prospects. Analyst Commentary Street research on Merck continues to highlight a constructive long term outlook balanced by execution and concentration risks, with recent notes refining expectations around valuation, pipeline durability, and capital allocation.분석 기사 • Dec 02
Merck (NYSE:MRK) Is Increasing Its Dividend To $0.85
Merck & Co., Inc. ( NYSE:MRK ) will increase its dividend from last year's comparable payment on the 8th of January to...내러티브 업데이트 • Nov 26
MRK: Recent Pipeline Deals And Patent Expiry Will Shape Outlook Ahead
Analysts have raised the price target for Merck to $105 from $98, citing stronger growth prospects and a more favorable valuation because of the company’s expanding pipeline and recent strategic deals. Analyst Commentary Recent analyst commentary on Merck highlights both positive momentum and notable risks that could influence the company’s trajectory in the months ahead.분석 기사 • Nov 02
Merck & Co., Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Merck & Co., Inc. ( NYSE:MRK ) came out with its quarterly results last week, and we wanted to see how the business is...주주 수익률
| MRK | US Pharmaceuticals | US 시장 | |
|---|---|---|---|
| 7D | -0.4% | -0.1% | -0.3% |
| 1Y | 46.8% | 38.7% | 26.7% |
수익률 대 산업: MRK은 지난 1년 동안 38.7%의 수익을 기록한 US Pharmaceuticals 산업보다 더 좋은 성과를 냈습니다.
수익률 대 시장: MRK은 지난 1년 동안 26.7%를 기록한 US 시장보다 더 좋은 성과를 냈습니다.
주가 변동성
| MRK volatility | |
|---|---|
| MRK Average Weekly Movement | 3.4% |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.2% |
안정적인 주가: MRK는 지난 3개월 동안 US 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: MRK의 주간 변동성(3%)은 지난 1년 동안 안정적이었습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 1891 | 74,000 | Rob Davis | www.merck.com |
는 전 세계 헬스케어 회사로 운영되고 있습니다. 키트루다, 키트루다 큐렉스, 웰리레그, 가다실, 프로쿼드, M-M-R II, 베리박스, 박뉴밴스, 캡박시브, 로타텍 등 다양한 분야의 인체 건강 의약품을 제공합니다, 뉴모박스 23, 브리디온, 프리비미스, 디피시드, 저박사, 윈레바이어, 아뎀파스/버큐보, 오투바이레, 라게브리오, 아이센트리스/아이센트리스 HD, 델스트리고, 피펠트로, 벨소라, 자누비아 및 자누멧 브랜드가 있습니다. 또한 누플로어, 보빌리스/비스타, 보빌리스 크립티움, 바나민 브랜드로 동물용 의약품, 백신, 건강 관리 솔루션 및 서비스를 제공합니다, 에스트루메이트, 매트릭스, 레스플로, 주프레보, 리발로, 세이프가드, 엠+팩, 포실리스, 써컴벤트, 노빌리스/이노박스, 파라콕스와 코시백, 엑스졸트, 슬라이스, 임빅사, 클라나브, 아쿠아박/노박, 아쿠아플로, 플렉솔트 브랜드를 보유하고 있습니다; 올플렉스 축산 인텔리전스 솔루션; 브라벡토 원먼스, 브라벡토 인젝터블/퀀텀, 브라벡토 트리유노, 브라벡토 플러스, 센티넬 스펙트럼, 센티넬 플레이버 탭, 누멜비, 옵티뮨의 반려동물 제품, 노비백 NXT, 길벳맙, 오토맥스, 모메타맥스, 모메타맥스 울트라, 포사텍스, 카닌슐린/베슐린, 파나큐어, 세이프가드, 리구메이트, 프레스티지, 스칼리보/엑스스팟, 슈어펫케어, 홈어게인 브랜드가 있습니다.
Merck & Co., Inc. 기초 지표 요약
| MRK 기초 통계 | |
|---|---|
| 시가총액 | US$282.15b |
| 순이익 (TTM) | US$8.94b |
| 매출 (TTM) | US$65.77b |
31.2x
주가수익비율(P/E)4.2x
주가매출비율(P/S)MRK는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| MRK 손익계산서 (TTM) | |
|---|---|
| 매출 | US$65.77b |
| 매출원가 | US$15.31b |
| 총이익 | US$50.46b |
| 기타 비용 | US$41.53b |
| 순이익 | US$8.94b |
최근 보고된 실적
Mar 31, 2026
다음 실적 발표일
Aug 04, 2026
| 주당순이익(EPS) | 3.62 |
| 총이익률 | 76.73% |
| 순이익률 | 13.59% |
| 부채/자본 비율 | 106.9% |
MRK의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기배당
3.0%
현재 배당 수익률91%
배당 성향기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/20 00:34 |
| 종가 | 2026/05/20 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Merck & Co., Inc.는 48명의 분석가가 다루고 있습니다. 이 중 7명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| David Toung | Argus Research Company |
| Charles Butler | Barclays |
| Emily Field | Barclays |